In China, lung cancer is a primary cancer type with high incidence and mortality. Risk factors
for lung cancer include tobacco use, family history, radiation exposure, and the presence of …

Estrogen receptor-positive (ER+) breast cancer is the most common breast cancer subtype.
Treatment of ER+ breast cancer comprises interventions that suppress estrogen production …

Although many kinds of therapies are applied in the clinic, drug-resistance is a major and
unavoidable problem. Another disturbing statistic is the limited number of drug targets, which …

Bladder cancer is a heterogeneous malignancy and is responsible for approximately 3.2%
of new diagnoses of cancer per year (Sung et al., 2021). Fibroblast Growth Factor Receptors …

The advent of precision medicine has brought light to the treatment of non-small cell lung
cancer (NSCLC), expanding the options for patients with advanced NSCLC by targeting …

Important advancements in the treatment of non-small cell lung cancer (NSCLC) have been
achieved over the past two decades, increasing our understanding of the disease biology …

While the potential of patient-derived organoids (PDOs) to predict patients' responses to anti-
cancer treatments has been well recognized, the lengthy time and the low efficiency in …

Patient-derived tumor xenografts (PDXs), in which tumor fragments surgically dissected from
cancer patients are directly transplanted into immunodeficient mice, have emerged as a …

Background Erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase
inhibitor, was shown to be clinically active and tolerable in patients with advanced urothelial …

Lung cancer, the leading cause of cancer mortality, exhibits heterogeneity that enables
adaptability, limits therapeutic success, and remains incompletely understood. Single-cell …